Signant Health Teams Up with Lothar Medical for Pulmonary Technology Innovations

Collaboration Between Signant Health and Lothar Medical

In a significant development for clinical trials, Signant Health, known for its expertise in evidence generation solutions, has partnered with Lothar Medical to commercialize the innovative ALDS PRO respiratory assessment system. This collaboration promises to revolutionize how clinical trials assess pulmonary function and treatment efficacy.

Overview of the Collaboration

On September 5, 2026, the two companies signed a letter of intent outlining their plans for a strategic partnership. The aim is to integrate Signant's electronic clinical outcome assessment (eCOA) solutions, particularly the TrialMax® platform, with Lothar Medical's advanced ALDS PRO system. This combined offering seeks to provide a comprehensive method for measuring both patient-reported outcomes and objective parameters of pulmonary function.

What is ALDS PRO?

The ALDS PRO system stands out due to its capability of incorporating three vital respiratory assessments: spirometry, airway oscillometry, and fractional exhaled nitric oxide (FeNO) in a single, portable unit. By unifying these assessments into one device, ALDS PRO reduces the complexity and fragmentation often encountered in clinical trial settings. It simplifies training and maintenance for clinical sites, ensuring a more streamlined data collection process.

By utilizing oscillometry alongside spirometry and FeNO, clinical trials can capture detailed information about airway mechanics while measuring inflammation in the lungs. This integration promises to minimize operational challenges and enhance the quality of data gathered during research.

The Future of Pulmonary Assessment in Clinical Trials

As part of their commercialization strategy, Signant intends to act as the exclusive provider of ALDS PRO for drug trials. Together, Signant and Lothar Medical will navigate the necessary scientific, technical, operational, and commercial procedures to ensure the system is fully prepared for use by clinical research sites and sponsors.

Roger Smith, CEO of Signant Health, emphasized the necessity for evidence that mirrors both patient experiences and the physiological aspects of diseases in respiratory research. The partnership is strategically aligned with Signant’s Sensor-Enhanced eCOA (SEE) initiative, which merges patient-reported outcomes with sensor-derived data for more accurate trial results.

Availability and Demonstrations

The announcement coincides with the European Respiratory Society International Congress taking place in Barcelona from September 5-9, 2026. Both companies will showcase ALDS PRO at their booth, offering demonstrations on how the device integrates comprehensive pulmonary assessments with digital health technologies derived from patient data.

Attendees can expect to gain insights into how these combined technologies will contribute to a more holistic understanding of patient health in clinical trials focused on respiratory conditions. The demonstration aims to illustrate the functionality and potential of the integrated system, although the actual combined product will not be commercially available at this time.

Conclusion

The collaboration between Signant Health and Lothar Medical marks a pivotal step towards enhancing the effectiveness and efficiency of pulmonary assessments in clinical settings. With increasing demands for detailed and actionable evidence in respiratory trials, the integration of ALDS PRO and Signant's eCOA solutions could pave the way for improved patient outcomes in clinical research.

For further updates on this exciting partnership, stay tuned as the companies prepare for a future where clinical trials can offer deeper insights into respiratory health and effectiveness of therapies.